Revvity (NYSE:RVTY) Issues FY 2026 Earnings Guidance

Revvity (NYSE:RVTY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 5.200-5.300 for the period, compared to the consensus EPS estimate of 5.400. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $3.0 billion.

Revvity Stock Performance

RVTY opened at $86.79 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30. The company has a 50 day simple moving average of $90.39 and a two-hundred day simple moving average of $96.82. The firm has a market cap of $9.70 billion, a P/E ratio of 41.73, a PEG ratio of 1.85 and a beta of 1.05.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The firm had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.20 million. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Equities analysts forecast that Revvity will post 5.39 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s payout ratio is presently 13.46%.

Analysts Set New Price Targets

RVTY has been the subject of several research analyst reports. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings lowered shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Robert W. Baird reduced their price target on shares of Revvity from $129.00 to $125.00 and set an “outperform” rating for the company in a report on Monday. TD Cowen reiterated a “hold” rating on shares of Revvity in a research note on Tuesday, February 3rd. Finally, Evercore lifted their price objective on shares of Revvity from $112.00 to $118.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revvity currently has a consensus rating of “Hold” and a consensus price target of $109.36.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently made changes to their positions in RVTY. Baird Financial Group Inc. raised its stake in Revvity by 17.2% in the 2nd quarter. Baird Financial Group Inc. now owns 3,333 shares of the company’s stock valued at $322,000 after purchasing an additional 488 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in Revvity during the third quarter worth about $294,000. Nomura Holdings Inc. acquired a new stake in Revvity during the third quarter worth about $270,000. Inceptionr LLC acquired a new stake in Revvity during the fourth quarter worth $263,000. Finally, Lido Advisors LLC purchased a new stake in shares of Revvity in the 4th quarter valued at approximately $211,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.